| Technology Name | Briefcase | Lead Researcher |
|---|---|---|
About the company
Raziel Therapeutics is a clinical-stage pharmaceutical company developing a proprietary drug (NCE) that after a single injection into subcutaneous fat, converts white adipose tissue (WAT) into thermogenic, brown-like adipose ... More | Ben-Sasson Shmuel | |
Company Profile
Splisense is developing targeted therapies for genetic diseases based on splicing modulation treating the underlying root cause of the disease.
SpliSense’s initial focus is on Cystic Fibrosis. SpliSense is developing a new ... More | Kerem Batsheva | |
Company Profile
Tissue Dynamics Ltd. is a groundbreaking biotechnology company advancing smart microphysiological platforms for drug, food, and cosmetic development. The company’s proprietary tissue-embedded micro sensors permit real time ... More | Nahmias Yaakov | |
Next-Generation Accelerators for Proton Beam Radiotherapy
Investment/ Collaboration Opportunity Highlights:
Investment round
Strategic co-development opportunitiesAbout the company
HIL Applied Medical is developing a new class of proton ... More | Zigler Arie | |
Current CEO: Ariel Shrem
About the Company
Guide In Medical is a medical device company specializing in airway management and respiration. The company is ISO 13485 certified and received the CE Mark, FDA, Health Canada and Israeli marketing ... More | Shrem Ariel | |
Year Company was Founded
2015
Company Founder
Prof Simon Benita
Current CEO
Alon Moran
About the Company
Based on decades of research by its founder and chairman, Prof. Simon Benita, a world-renowned scientist of nanotechnology, inventor of ... More | Benita Simon | |
Company Founder
Shuki Herchovici
Current CEO
Dr. Nikolai Kunicher
About the Company
Betalin Therapeutics is developing a revolutionary therapy for diabetes treatment. Our engineered micro pancreas (EMP) aims to replace insulin therapy for ... More | Mitrani Eduardo | |
About The Company
Established in 2003 by Prof. Raymond Kaempfer and Dr. Gila Arad, AtoxBio is a late stage biotech company that develops novel immunomodulators for fighting infectious diseases by targeting the host immune system, rather than ... More | Kaempfer Raymond | |
The Challenge
Drug resistance is a major cause for failure of cancer chemotherapy. In present clinical practice, resistance to chemotherapy can only be recognized after the first course of treatment has been completed, yielding no major clinical ... More | Benvenisty Nissim | |
AT A GLANCE
Established by Integra Holdings and XL Vision Sciences, fully owned by BioLight Lifesciences Investments, in 2014, OPhRx is developing novel drug products for topical administration for diseases involving front-of the eye and back of ... More | Garti Nissim | |
AT A GLANCE
Established by Integra Holdings in 2017, Nectin Therapeutics is developing novel monoclonal antibodies directed towards Nectin receptors and ligands, playing major roles in immune checkpoint mechanisms relevant for cancer immune ... More | Mandelboim Ofer | |
Company Name
LDS Lyotropic Delivery Systems Ltd.
Company Founders
Professor Nissim Garti
Current CEO
Professor Nissim Garti
About the Company
LDS is a privately owned nano and biotechnology company focusing on the development of novel liquid ... More | Garti Nissim | |
Company Name
Aferrix
Company Founders
Prof. Zvi Ioav Cabantchik,
Current CEO
Yael Furman, Ms.C., MBA, CEO
About the Company
Aferrix is an innovative leader in development and applications of novel tools for early diagnosis and monitoring of ... More | Cabantchik Ioav | |
Company Name
CardioVIa
Current CEO
Ziv Menshes
About the Company
CardioVia provides physicians with a minimally invasive access capability to the heart through the pericardium in order to treat the most prevalent Cardiovascular Diseases and ... More | Buxboim Amnon |